Taisho Pharmaceutical Co., Ltd.

Aya Futamura

Ryo Suzuki

Hiroshi Ohta

Toshio Nakamura

Masahito Abe

Dai Nozawa

Hiroki Urabe

Seiji Masuda

Norikazu Otake

Yuko Araki

Nobutaka Hattori

Hideaki Tabuse

Koreaki Imura

Takaaki Matsubara

Ryo Kinoshita

Provided is a novel process for producing a (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative. More specifically, provided is a process for producing a (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative represented by formula (1): 

Method for producing (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative

A heteroaromatic methyl cyclic amine derivative represented by formula (IA) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorder, cephalalgia, hemicrania, pain, digestive diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases and hypertension, on the basis of an orexin (OX) receptor antagonist activity. 

Heteroaromatic methyl cyclic amine derivative

The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases. A dihydroquinolinone derivative represented by formula (1) or a pharmaceutically acceptable salt thereof: {wherein Q represents the following formula (A) or (B)} 

Dihydroquinolinone derivatives

Growing community of inventors

Tokyo, Japan

Aya Futamura